Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer

Fineline Cube Feb 28, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...

Company Drug

Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval

Fineline Cube Feb 28, 2025

China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...

Company Drug

Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL

Fineline Cube Feb 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...

Company Deals

EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases

Fineline Cube Feb 27, 2025

EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...

Company Drug

AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study

Fineline Cube Feb 27, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...

Company Drug

Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study

Fineline Cube Feb 27, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...

Company

Ping An Good Doctor Launches AI-Powered Digital Doctor Service

Fineline Cube Feb 27, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company

Eli Lilly to Establish Four New US Pharma Manufacturing Sites

Fineline Cube Feb 27, 2025

US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...

Company Drug

Precigen’s RRP Therapy PRGN-2012 Gets FDA Review

Fineline Cube Feb 27, 2025

US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...

Company Deals

Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine

Fineline Cube Feb 27, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with...

Company Deals

Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field

Fineline Cube Feb 27, 2025

Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...

Company Drug

InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum

Fineline Cube Feb 27, 2025

Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...

Company Drug

Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia

Fineline Cube Feb 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...

Company Drug

Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases

Fineline Cube Feb 27, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow...

Company Medical Device

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Fineline Cube Feb 27, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare...

Company Drug

Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients

Fineline Cube Feb 27, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...

Company Deals

WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development

Fineline Cube Feb 26, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Kexing Biopharm and Bio-Sincerity Pharmaceutical Form Strategic Alliance

Fineline Cube Feb 26, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) and Hangzhou Bio-Sincerity Pharmaceutical Technology Co., Ltd. (SHE:...

Company Deals

Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy

Fineline Cube Feb 26, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed...

Company Deals Hospital

Basecare and Rhea Labs Form Five-Year Alliance to Expand IVF Markets Globally

Fineline Cube Feb 26, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has entered into a five-year...

Posts pagination

1 … 197 198 199 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.